Cost–utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea. (2nd September 2019)

• Record Type: Journal Article
• Authors: Han, Sola; Kim, Siin; Kim, Hyungtae; Suh, Hae Sun
• Is Part Of: Current medical research and opinion. Volume 35:Number 9(2019)
• Page Start: 1597
• Page End: 1605
• Publication Date: 2019-09-02
• Subjects: Asthma -- reslizumab -- eosinophils -- cost–effectiveness analysis; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2019.1605159
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objectives: We aimed to assess the cost-utility of reslizumab for patients with severe eosinophilic asthma uncontrolled with high-dose inhaled corticosteroids and long-acting β2 -agonists (ICS/LABAs) in Korea. Methods: A Markov model with limited societal perspective was used to compare the costs and quality-adjusted life years (QALYs) of reslizumab add-on therapy with standard-of-care (high-dose ICS/LABA) and standard-of-care alone. The model adopted a 4 week cycle with the following six health states over a lifetime (60 years): controlled asthma, uncontrolled asthma, moderate exacerbation, severe exacerbation, all-cause death and asthma-related death. The population comprised adult patients (age ≥18 years) with severe eosinophilic asthma (eosinophils ≥400 cells/μL) at Global Initiative for Asthma (GINA) step 4 or 5 who had experienced at least three exacerbations in the preceding year. Model inputs were sourced from individual patient-level data from two 52 week randomized controlled trials of reslizumab (NCT01287039, NCT01285323). The model included discontinuation rules where patients uncontrolled with reslizumab add-on therapy were transitioned to the standard-of-care arm. Costs and QALYs were annually discounted at 5%. Deterministic and probabilistic sensitivity analyses were performed. Results: Reslizumab add-on therapy was associated with increased cost (US$119, 394) and improved QALYs (5.17) compared with standard-of-care alone, resulting in an incremental cost-effectiveness ratio of US$23, 081 per QALY gained. Body weight, time horizon and discount rate were influential factors in the model. Conclusions: The addition of reslizumab to high-dose ICS/LABA was cost-effective in Korean patients with severe eosinophilic asthma uncontrolled with high-dose ICS/LABA, based on the threshold of 1 gross domestic product in Korea. Trial registration: ClinicalTrials.gov identifier: NCT01285323. Trial registration: ClinicalTrials.gov identifier: NCT01287039.